Oral News and Research

RSS

Gentium to present three abstracts on Defibrotide at American Society of Hematology

Gentium S.p.A. today announced that three abstracts on Defibrotide will be presented at the 52nd Annual Meeting and Exposition of the American Society of Hematology to be held at the Orange County Convention Center in Orlando, Florida, December 4-7, 2010.

10 Nov 2010

Hemispherx Biopharma awarded grant for Ampligen, Alferon development programs

Hemispherx Biopharma, Inc. announced today grant awards totaling $488,958 from the U.S. Department of Treasury in support of its Ampligen and Alferon development programs.

10 Nov 2010

Covidien analysis finds lower incidence of GI adverse events with topical NSAIDs versus oral

Covidien, a leading global provider of healthcare products, announced the results of an analysis that will be presented at the American College of Rheumatology's Annual Scientific Meeting. A pooled analysis of safety data suggests that patients with knee osteoarthritis (OA) receiving the topical PENNSAID® (diclofenac sodium topical solution) 1.5% w/w had significantly fewer gastrointestinal (GI)-related adverse events than those receiving an oral non-steroidal anti-inflammatory drug (NSAID).

10 Nov 2010

TRU-016 abstracts to be presented at ASH meeting

Emergent BioSolutions Inc. today announced the acceptance of four abstracts for presentation at the 52nd Annual Meeting of the American Society of Hematology to be held from December 4 to 7 in Orlando, Florida. The presentations include an oral presentation on the results of a Phase I dose escalation, monotherapy study of TRU-016 for patients with chronic lymphocytic leukemia.

10 Nov 2010

Fibroblast growth factor-2 stimulates periodontal regeneration: Study

It is well known that oral infection progressively destroys periodontal tissues and is the leading cause of tooth loss in adults. A major goal of periodontal treatment is regeneration of the tissues lost to periodontitis. Unfortunately, most current therapies cannot predictably promote repair of tooth-supporting defects. A variety of regenerative approaches have been used clinically using bone grafts and guiding tissue membranes with limited success.

10 Nov 2010

Myrexis presents key preclinical findings of MPI-0485520 at ACR/ARHP meeting

Myrexis, Inc., a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today presented key preclinical findings of the Company's novel oral anti-interferon, MPI-0485520, at the 74th Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals, in Atlanta, Georgia.

10 Nov 2010

Regional workshop to discuss diarrheal disease solutions for Asia

Each year, diarrheal disease claims the lives of 1.3 million children under five worldwide and hospitalizes millions more. The vast majority of these deaths occur in developing countries of Asia and Africa, but fortunately, interventions exist that can greatly reduce deaths and save lives. To bring attention to the solutions available today for defeating diarrhea, the Vietnam Ministry of Health, the National Pediatric Hospital of Vietnam, and PATH are hosting a two-day regional workshop where they will present the evidence and lessons learned from initiatives currently underway.

10 Nov 2010

Cholera confirmed in Haiti's capital as health ministry says outbreak has killed 544 so far

Haiti's cholera outbreak appears to have spread to its capital, "imperiling nearly 3 million people living in Port-au-Prince, nearly half of them in unsanitary tent camps for the homeless from the Jan. 12 earthquake," the Associated Press/KIRO reports.

10 Nov 2010

New York Times examines HIV prevention products undergoing clinical trials

The New York Times examines several products being studied in clinical trials that researchers hope will one day prevent sexual transmission of HIV. The newspaper describes the ongoing trials of a vaginal microbicide gel containing the antiretroviral tenofovir which was found to reduce the risk of HIV infection in women by 39 percent, writing, "[o]ther clinical trials will report their results in 2011 and 2012 and, if all goes well, researchers hope to have a product or two ready to enter the market by 2013."

10 Nov 2010

Phytomedics awarded $244,000 QTDP grant for development of RA drug

Phytomedics, Inc., a transformational healthcare company developing a novel portfolio of drugs and consumer products solely derived from plant sources, announced today that it has been awarded a grant in the amount of $244,000 under the Qualifying Therapeutic Discovery Project (QTDP) Program to advance the development of its lead product PMI-001 for Rheumatoid Arthritis. PMI-001 is presently in Phase 2b/3 development.

9 Nov 2010

ARIAD reports $20.4 million net loss for third quarter 2010

ARIAD Pharmaceuticals, Inc. today reported financial results for the third quarter and nine months ended September 30, 2010 and provided an update on corporate developments.

9 Nov 2010

Innovative method for in-cell gene manipulation

A cross-disciplinary Small Medicine and Advanced Research Translation (SMART) team led by Prof. Dar-Bin Shieh of Institute of Oral Medicine in Medical College at National Cheng Kung University (NCKU), Tainan, Taiwan, has announced a breakthrough in the precision in-cell gene scission at pre-designed sequence sites using Artificial Targeting Light Activated Nano Scissors (ATLANS) and a custom build photonic device.

9 Nov 2010

Research demonstrates a safe method to control malaria in Africa

Research carried out in Mali, West Africa, has demonstrated that a new, safe and uncomplicated insect control method, developed at the Hebrew University of Jerusalem, can bring about a serious decline in malaria-bearing mosquitoes in afflicted regions in the world.

9 Nov 2010

ORAL Solo Phase 3 study shows tasocitinib reduces signs and symptoms of active RA

Pfizer Inc. today announced results of ORAL Solo (1045), a Phase 3 study that showed tasocitinib (CP-690,550), an investigational, novel, oral JAK inhibitor, administered as monotherapy met two primary endpoints, demonstrating a statistically significant reduction in signs and symptoms of moderately to severely active rheumatoid arthritis (RA) and improvement in physical function as measured by ACR20 response rates and mean change in HAQ-DI, respectively, versus placebo at three months.

9 Nov 2010

Seattle Genetics, Millennium to feature SGN-35 in two oral presentations at ASH Annual Meeting

Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited today announced that brentuximab vedotin (SGN-35) will be featured in two oral presentations at the 52nd American Society of Hematology (ASH) Annual Meeting and Exposition being held December 4-7, 2010 in Orlando, FL.

9 Nov 2010

Genta commences tesetaxel Phase 2b clinical trial as 1st-line chemotherapy for metastatic breast cancer

Genta Incorporated today announced that the Company has initiated a new Phase 2b clinical trial of tesetaxel as 1st-line chemotherapy for women with metastatic breast cancer. Tesetaxel is the leading oral taxane currently in clinical development. The new trial will be conducted at Memorial Sloan-Kettering Cancer Center, New York, NY and at the Accelerated Community Oncology Research Network (ACORN) based in Memphis, TN.

9 Nov 2010

New data on Soliris for PNH treatment to be presented at ASH Annual Meeting

Alexion Pharmaceuticals, Inc. today announced that researchers are scheduled to present new data relating to Soliris (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) during the 52nd Annual Meeting of the American Society of Hematology (ASH), to be held December 4 - 7, 2010 at the Orange County Convention Center in Orlando.

9 Nov 2010

Calypte receives $244,479 tax credit under QTDP program

Calypte Biomedical Corporation, the developer, manufacturer and marketer of the Aware HIV-1/2 OMT (oral fluid) HIV test, announced today that it has been awarded a tax credit of $244,479 under U.S. Government's Qualifying Therapeutic Discovery Project (QTDP) program.

8 Nov 2010

Positive results from Ardea's RDEA594 combination study with febuxostat or allopurinol for gout

Ardea Biosciences, Inc. announced positive results from two clinical studies of RDEA594 in combination with currently marketed drugs for the treatment of gout patients, febuxostat (Uloric®) and allopurinol.

8 Nov 2010

Progenics third quarter net loss increases to $17.1 million

Progenics Pharmaceuticals, Inc. today announced its results of operations for the third quarter and nine months ended September 30, 2010.

8 Nov 2010

Oral News and Research

Gentium to present three abstracts on Defibrotide at American Society of Hematology

Hemispherx Biopharma awarded grant for Ampligen, Alferon development programs

Covidien analysis finds lower incidence of GI adverse events with topical NSAIDs versus oral

TRU-016 abstracts to be presented at ASH meeting

Fibroblast growth factor-2 stimulates periodontal regeneration: Study

Myrexis presents key preclinical findings of MPI-0485520 at ACR/ARHP meeting

Regional workshop to discuss diarrheal disease solutions for Asia

Cholera confirmed in Haiti's capital as health ministry says outbreak has killed 544 so far

New York Times examines HIV prevention products undergoing clinical trials

Phytomedics awarded $244,000 QTDP grant for development of RA drug

ARIAD reports $20.4 million net loss for third quarter 2010

Innovative method for in-cell gene manipulation

Research demonstrates a safe method to control malaria in Africa

ORAL Solo Phase 3 study shows tasocitinib reduces signs and symptoms of active RA

Seattle Genetics, Millennium to feature SGN-35 in two oral presentations at ASH Annual Meeting

Genta commences tesetaxel Phase 2b clinical trial as 1st-line chemotherapy for metastatic breast cancer

New data on Soliris for PNH treatment to be presented at ASH Annual Meeting

Calypte receives $244,479 tax credit under QTDP program

Positive results from Ardea's RDEA594 combination study with febuxostat or allopurinol for gout

Progenics third quarter net loss increases to $17.1 million

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News